Skip to content
Open access

MOLECULAR DOCKING STUDY OF INDONESIAN PLANT-DERIVED BIOACTIVE COMPOUND TARGETING ESTROGEN RECEPTOR ALPHA (1L2J) IN CERVICAL CANCER

Aug 2026 · Medical Sains : Jurnal Ilmiah Kefarmasian · 0 citations

TL;DR

Findings suggest that carissanol from Carissa spinarum L. is a promising natural lead compound targeting ER-?

Abstract

Cervical cancer remains a leading cause of cancer-related mortality among women worldwide, with estrogen receptor alpha (ER-?) playing a key role in carcinogenesis. Although tamoxifen is an established ER-? antagonist, its clinical use is limited by drug resistance and tissue-specific adverse effects. Indonesian medicinal plants contain diverse phytochemicals with potential as alternative ER-? inhibitors. This study evaluated the binding affinities and molecular interaction profiles of six Indonesian plant-derived bioactive compounds against the ER-? ligand-binding domain (PDB ID: 1L2J) using molecular docking in MOE 2015.10, with tamoxifen as the reference ligand. Docking validation by re-docking the native ligand produced an RMSD of 1.5487 Å, confirming the reliability of the protocol. Among the tested compounds, carissanol exhibited the strongest binding affinity (S-score: ?14.7293 kcal/mol), surpassing tamoxifen (?12.7112 kcal/mol), and formed a key hydrogen bond with Gln305, along with extensive hydrophobic interactions. Quercetin also demonstrated strong binding (?13.5099 kcal/mol), whereas piperidine showed the weakest affinity (?5.5143 kcal/mol). These findings suggest that carissanol from Carissa spinarum L. is a promising natural lead compound targeting ER-? and merits further in vitro and in vivo investigations. Keywords: Cervical cancer, Estrogen Receptor Alpha, Molecular Docking, Carissanol, 1L2J

Read PDF

Similar papers

Open access Aug 2026

Agonist potential of estrogen-β receptors from brown algae (Sargassum muticum) as molecular therapy for breast cancer: in-silico approach

The study shows that Eckol has the potential to act as an estrogen receptor β agonist, however, further research, such as in vitro testing, is needed to confirm this agonistic activity.

Mila Karisma Fitriawati, Fakih Haikal, Fadia Fatiha et al. · 0 citations
Aug 2026

Structure-based elucidation of thiazine inhibitors targeting estrogen receptors alpha: pharmacophore modeling, virtual screening, molecular docking, MD, and DFT approach.

This research developed a promising lead molecule (HIT1) as a therapeutic approach for ER-positive breast cancer through pharmacophore model-based drug design of thiazine derivative targeting ERα via pharmacophore model-based drug design.

M. Sanjeev, Bhim Singh, Kailash Jangid et al. · 0 citations
Open access Jul 2026

Ethanol Extract of Grass Jelly Leaves: Bioactive Analysis and In silico Study on Estrogen Receptor Alpha Related to MCF-7 Breast Cancer

Findings suggest that the compound (3β,24R,24′R)-fucosterol epoxide showed promising interaction stability toward the estrogen receptor in computational analysis, however, further in vitro and in vivo studies are required to validate its biological activity.

Abdul Irpani, A. Yuliantini, M. Bintang et al. · 0 citations
Aug 2026

Anticancer activity of lichen-derived compounds against triple-negative breast cancer: integrated in vitro evaluation, network pharmacology, molecular docking, and KEGG pathway analysis.

Lichen-derived compounds atranorin, barbatic acid, and usnic acid demonstrated anticancer activity in vitro, while integrated computational analyses suggested potential multitarget interactions that warrant further experimental validation.

Sachin V. Mapari, S. Gaikwad, Ruchira R. Sutar et al. · 0 citations
Open access Jul 2026

Exploring the Breast Cancer Inhibitor from Flavone Subclass: In Silico and In Vitro Assays

It is suggested that amentoflavone has potential as a natural lead compound for further optimization and development of ERα-targeted therapies in ER-positive breast cancer.

D. S. F. Ramadhan, Nurisyah Nurisyah, Asyhari Asyikin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.